Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Colorectal Neoplasms 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, B-Cell 2Lymphoma 2Leukemia 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Tinnitus 1Thrombocytopenia 1Squamous NSCLC 1Solid Tumors 1Sinusitis 1Rib Fractures 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ototoxicity 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myelomonocytic, Chronic 1

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Allogeneic Stem Cell Transplantation × 30 days × Clear all
NCT06297629 2026-05-15

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡